HRP20161024T1 - Novi derivati amino-pirolina i njihova uporaba u sprječavanju i/ili liječenju metaboličkog sindroma - Google Patents
Novi derivati amino-pirolina i njihova uporaba u sprječavanju i/ili liječenju metaboličkog sindroma Download PDFInfo
- Publication number
- HRP20161024T1 HRP20161024T1 HRP20161024TT HRP20161024T HRP20161024T1 HR P20161024 T1 HRP20161024 T1 HR P20161024T1 HR P20161024T T HRP20161024T T HR P20161024TT HR P20161024 T HRP20161024 T HR P20161024T HR P20161024 T1 HRP20161024 T1 HR P20161024T1
- Authority
- HR
- Croatia
- Prior art keywords
- branched
- straight
- alkyl
- hydrogen
- group
- Prior art date
Links
- 208000001145 Metabolic Syndrome Diseases 0.000 title claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 title claims 2
- 230000002265 prevention Effects 0.000 title claims 2
- NPLSMQWSKZXZPD-UHFFFAOYSA-N 2,3-dihydropyrrol-1-amine Chemical class NN1CCC=C1 NPLSMQWSKZXZPD-UHFFFAOYSA-N 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 22
- 239000001257 hydrogen Substances 0.000 claims 22
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 12
- 229910052736 halogen Inorganic materials 0.000 claims 12
- 150000002367 halogens Chemical class 0.000 claims 12
- 239000000126 substance Substances 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 150000002431 hydrogen Chemical class 0.000 claims 8
- 125000002252 acyl group Chemical group 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 6
- 150000003512 tertiary amines Chemical class 0.000 claims 6
- 150000003335 secondary amines Chemical class 0.000 claims 5
- 150000003141 primary amines Chemical class 0.000 claims 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 3
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 3
- 239000004721 Polyphenylene oxide Chemical group 0.000 claims 3
- 150000001336 alkenes Chemical class 0.000 claims 3
- 150000001602 bicycloalkyls Chemical group 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 229920000570 polyether Chemical group 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (14)
1. Tvari sljedeće opće formule (I):
[image]
pri čemu
a) svaki R12 predstavlja H, i
R1 i R2 su svaki nezavisno:
halogen, ravnolančani ili razgranati C1 do C8 alkil, C2-C8 alken, ravnolančani ili razgranati C1 do C8 alkoksi, C3-C6 cikloalkil, C5-C6 bicikloalkil, polieterni lanac, C1-C5 perfluoroalkil, C1-C8 acil, OH, SH, primarni, sekundarni ili tercijarni amin, CN, CO2H, CO2R' gdje je R' ravnolančani ili razgranati C1-C8 alkil ili C3-C6 cikloalkil; ili R1 i R2 zajedno čine C5 prsten
R3, R4 i R5 svaki nezavisno predstavljaju:
vodik, Halogen, ravnolančani ili razgranati C1 do C8 alkil, C2-C8 alken, ravnolančani ili razgranati C1 do C8 alkoksi, C3-C6 cikloalkil, C5-C6 bicikloalkil, polieterni lanac, C1-C5 perfluoroalkil, C1-C8 acil, OH, SH, primarni, sekundarni ili tercijarni amin, CN, CO2H, CO2R' gdje je R' ravnolančani ili razgranati C1-C8 alkil ili C3-C6 cikloalkil;
R6, R7, R9 i Rll predstavljaju vodike;
R8 i R10 su izabrani iz grupe koja se sastoji od vodika i ravnolančanog ili razgranatog
Cl do C5 alkila, najmanje jedan od njih je ravnolančani ili razgranati C1 do C5 alkil;
b) ili R12 predstavlja CH(R13)(CH2) i čini C5 prsten s R, R13 predstavlja H ili CH3,
R1, R2, R3 i R4 su izabrani iz grupe koja se sastoji od vodika, halogena, ravnolančanog ili razgranatog C1 do C8 alkila, C2-C8 alkena, ravnolančanog ili razgranatog C1 do C8 alkoksi, C3-C6 cikloalkila, C5-C6 bicikloalkila, polietemog lanca, C1-C5 perfluoroalkila, C1-C8 acila, OH, SH, primarnog, sekundarnog ili tercijarnog amina, CN, CO2H, CO2R' gdje je R' ravnolančani ili razgranati C1-C8 alkil ili C3-C6 cikloalkil; R6, R7 i R11 predstavljaju vodike;
R8 i R10 su izabrani iz grupe koja se sastoji od vodika i ravnolančanog ili razgranatog C1 do C5 alkila, najmanje jedan od njih je ravnolančani ili razgranati C1 do C5 alkil,
uz uvjet da najmanje jedan između R1 i R13 nije vodik;
i njihove farmaceutski prihvatljive soli.
2. Tvari u skladu s patentnim zahtjevom 1 sljedeće opće formule (Ia):
[image]
pri čemu
R3 i R12 su vodici;
R8 i R10 su izabrani iz grupe koja se sastoji od vodika i ravnolančanog ili razgranatog C1 do C5 alkila, najmanje jedan od njih je ravnolančani ili razgranati C1 do C5 alkil; i R4 i R5 su nezavisno odabrani iz grupe koja se sastoji od vodika, halogena, ravnolančanog ili razgranatog C1 do C3 alkila, ravnolančanog ili razgranatog C1 do C3 alkoksi, C1-C3 perfluoroalkila, C1-C3 acila, OH, SH, primarnog, sekundarnog ili tercijarnog amina, CN, CO2H, CO2R' gdje je R' ravnolančani ili razgranati C1-C3 alkil, poželjno iz grupe koja se sastoji od halogena, ravnolančanog ili razgranatog C1 do C3 alkila, ravnolančanog ili razgranatog C1 do C3 alkoksi, C1-C3 perfluoroalkila i C1-C3 acila.
3. Tvari u skladu s patentnim zahtjevom 2 pri čemu su R4 i R5 vodici.
4. Tvari u skladu s patentnim zahtjevom 1 sljedeće opće formule (Ib):
[image]
pri čemu:
R12 je vodik;
R8 i R10 su izabrani iz grupe koja se sastoji od vodika i ravnolančanog ili razgranatog C1 do C5 alkila, najmanje jedan od njih je ravnolančani ili razgranati C1 do C5 alkil;
R1 i R2 su nezavisno odabrani iz grupe koja se sastoji od halogena, ravnolančanog ili razgranatog C1 do C3 alkila, ravnolančanog ili razgranatog C1 do C3 alkoksi, C1-C3 perfluoroalkila i C1-C3 acila; i
R3, R4 i R5 su nezavisno odabrani iz grupe koja se sastoji od vodika, halogena, ravnolančanog ili razgranatog C1 do C3 alkila, ravnolančanog ili razgranatog C1 do C3 alkoksi, C1-C3 perfluoroalkila, C1-C3 acila, OH, SH, primarnog, sekundarnog ili tercijarnog amina, CN, CO2H, CO2R' gdje je R' ravnolančani ili razgranati C1-C3 alkil, poželjno iz grupe koja se sastoji od halogena, ravnolančanog ili razgranatog C1 do C3 alkila, ravnolančanog ili razgranatog C1 do C3 alkoksi, C1-C3 perfluoroalkila i C1-C3 acila.
5. Tvari u skladu s patentnim zahtjevom 4 pri čemu su R3, R4 i R5 vodici.
6. Tvari u skladu s patentnim zahtjevom 4 ili 5 pri čemu su R1 i R2 nezavisno odabrani iz grupe koja se sastoji od halogena i ravnolančanog ili razgranatog C1 do C3 alkila.
7. Tvar u skladu s jednim od patentnih zahtjeva 1 do 6 odabrana između jedne od sljedećih formula:
[image]
8. Tvari u skladu s patentnim zahtjevom 1 sljedeće opće formule (Ic):
[image]
pri čemu:
R1, R2, R3 i R4 su nezavisno odabrani iz grupe koja se sastoji od vodika, halogena, ravnolančanog ili razgranatog C1 do C3 alkila, ravnolančanog ili razgranatog C1 do C3 alkoksi, C1-C3 perfluoroalkila i C1-C3 acila, OH, SH, primarnog, sekundarnog ili tercijarnog amina, CN, CO2H, CO2R' gdje je R' ravnolančani ili razgranati C1-C3 alkil;
R8 i RIO su izabrani iz grupe koja se sastoji od vodika i ravnolančanog ili razgranatog C1 do C5 alkila, najmanje jedan od njih je vodik, uz uvjet da najmanje jedan između R1 i R13 nije vodik.
9. Tvari u skladu s patentnim zahtjevom 8 pri čemu:
R2, R3 i R4 su vodici,
R13 je H i R1 je halogen i ravnolančani ili razgranati C1 do C3 alkil; ili R13 je metil i R1 je odabran iz grupe koja se sastoji od vodika, halogena i ravnolančanog ili razgranatog C1 do C3 alkila; i
R8 i R10 su odabrani iz grupe koja se sastoji od vodika i ravnolančanog ili razgranatog C1 do C5 alkila, najmanje jedan od njih je vodik.
10. Tvari u skladu s patentnim zahtjevom 8 ili 9 odabrane između jedne od sljedećih formula:
[image]
11. Tvari kako su definirane u jednom od patentnih zahtjeva 1 do 10 za uporabu u sprječavanju i/ili liječenju metaboličkog sindroma.
12. Farmaceutski sastav kao aktivni sastojak sadrži najmanje jednu tvar u skladu s jednim od patentnih zahtjeva 1 do 10 udruženu s farmaceutski prihvatljivim nosačem.
13. Farmaceutski sastav u skladu s patentnim zahtjevom 12 koji se može primijeniti oralnim putem.
14. Farmaceutski sastav koji se može primijeniti oralnim putem u skladu s patentnim zahtjevom 13 pri čemu je doza aktivnog sastojka između 1 mg/kg i 100 mg/kg u čovjeka.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1153375A FR2974364B1 (fr) | 2011-04-19 | 2011-04-19 | Nouveaux derives amino-pyrroliniques, leur utilisation dans la prevention et/ou le traitement du syndrome metabolique |
| FR1251302 | 2012-02-13 | ||
| PCT/FR2012/050835 WO2012143660A1 (fr) | 2011-04-19 | 2012-04-17 | Nouveaux derives amino-pyrroliniques, leur utilisation dans la prevention et/ou le traitement du syndrome metabolique |
| EP12722423.6A EP2699545B1 (fr) | 2011-04-19 | 2012-04-17 | Nouveaux derives amino-pyrroliniques, leur utilisation dans la prevention et/ou le traitement du syndrome metabolique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20161024T1 true HRP20161024T1 (hr) | 2016-11-04 |
Family
ID=46146922
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161024TT HRP20161024T1 (hr) | 2011-04-19 | 2016-08-16 | Novi derivati amino-pirolina i njihova uporaba u sprječavanju i/ili liječenju metaboličkog sindroma |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9303019B2 (hr) |
| EP (1) | EP2699545B1 (hr) |
| JP (1) | JP5986625B2 (hr) |
| CN (1) | CN103619814B (hr) |
| CA (1) | CA2833339C (hr) |
| CY (1) | CY1118117T1 (hr) |
| DK (1) | DK2699545T3 (hr) |
| ES (1) | ES2588059T3 (hr) |
| HR (1) | HRP20161024T1 (hr) |
| HU (1) | HUE030432T2 (hr) |
| LT (1) | LT2699545T (hr) |
| PL (1) | PL2699545T3 (hr) |
| PT (1) | PT2699545T (hr) |
| RS (1) | RS55061B1 (hr) |
| SI (1) | SI2699545T1 (hr) |
| SM (1) | SMT201600284B (hr) |
| WO (1) | WO2012143660A1 (hr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2015007710A (es) * | 2012-12-19 | 2015-09-23 | Bayer Cropscience Ag | Indanilcarboxamidas difluorometil-nicotinicas. |
| WO2023084054A1 (en) | 2021-11-12 | 2023-05-19 | 3Z Ehf | Treatment of adhd using selective binders of the 11-imidazoline receptor |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1670859A1 (de) | 1967-04-24 | 1971-03-11 | Bayer Ag | Verfahren zur Herstellung von 2-Phenyl-imino-1-azacycloalkanen |
| US3679692A (en) * | 1969-10-01 | 1972-07-25 | Mead Johnson & Co | Iminomethylindolines |
| US4533739A (en) * | 1982-10-12 | 1985-08-06 | G. D. Searle & Co. | 2-[(Aminophenyl and amidophenyl)amino]-1-azacycloalkanes having antidiarrheal activity |
| US4579951A (en) * | 1984-03-19 | 1986-04-01 | G. D. Searle & Co. | Substituted (azacycloalk-2-yl)iminophenols and esters thereof |
| CA2777223C (en) * | 2009-10-06 | 2017-10-24 | Allergan, Inc. | 2h-pyrrol-5-amine derivatives as alpha adrenergic receptor modulators |
| US20120238615A1 (en) * | 2009-10-21 | 2012-09-20 | Allergan, Inc. | Alpha adrenergic receptor modulators |
-
2012
- 2012-04-17 JP JP2014505700A patent/JP5986625B2/ja not_active Expired - Fee Related
- 2012-04-17 HU HUE12722423A patent/HUE030432T2/en unknown
- 2012-04-17 WO PCT/FR2012/050835 patent/WO2012143660A1/fr active Application Filing
- 2012-04-17 SI SI201230681A patent/SI2699545T1/sl unknown
- 2012-04-17 PT PT127224236T patent/PT2699545T/pt unknown
- 2012-04-17 US US14/112,631 patent/US9303019B2/en not_active Expired - Fee Related
- 2012-04-17 DK DK12722423.6T patent/DK2699545T3/en active
- 2012-04-17 ES ES12722423.6T patent/ES2588059T3/es active Active
- 2012-04-17 PL PL12722423T patent/PL2699545T3/pl unknown
- 2012-04-17 LT LTEP12722423.6T patent/LT2699545T/lt unknown
- 2012-04-17 EP EP12722423.6A patent/EP2699545B1/fr active Active
- 2012-04-17 CA CA2833339A patent/CA2833339C/fr not_active Expired - Fee Related
- 2012-04-17 CN CN201280019520.6A patent/CN103619814B/zh not_active Expired - Fee Related
- 2012-04-17 RS RS20160689A patent/RS55061B1/sr unknown
-
2016
- 2016-08-16 HR HRP20161024TT patent/HRP20161024T1/hr unknown
- 2016-08-22 CY CY20161100829T patent/CY1118117T1/el unknown
- 2016-08-23 SM SM201600284T patent/SMT201600284B/it unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RS55061B1 (sr) | 2016-12-30 |
| HUE030432T2 (en) | 2017-05-29 |
| EP2699545B1 (fr) | 2016-05-25 |
| US20140045910A1 (en) | 2014-02-13 |
| JP5986625B2 (ja) | 2016-09-06 |
| CN103619814A (zh) | 2014-03-05 |
| CA2833339C (fr) | 2020-09-15 |
| PL2699545T3 (pl) | 2017-01-31 |
| LT2699545T (lt) | 2016-09-26 |
| PT2699545T (pt) | 2016-08-30 |
| ES2588059T3 (es) | 2016-10-28 |
| SMT201600284B (it) | 2016-11-10 |
| EP2699545A1 (fr) | 2014-02-26 |
| SI2699545T1 (sl) | 2016-12-30 |
| US9303019B2 (en) | 2016-04-05 |
| WO2012143660A1 (fr) | 2012-10-26 |
| CY1118117T1 (el) | 2017-06-28 |
| DK2699545T3 (en) | 2016-08-29 |
| CN103619814B (zh) | 2016-01-20 |
| JP2014514316A (ja) | 2014-06-19 |
| CA2833339A1 (fr) | 2012-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200561T1 (hr) | Prolijekovi spoja jak inhibitora za liječenje gastrointestinalnih upalnih bolesti | |
| HRP20161103T1 (hr) | Kemijski spojevi | |
| RU2477723C2 (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
| HRP20161428T1 (hr) | Modulatori farmakokinetičkih svojstava lijekova | |
| BR112014019478A2 (pt) | composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, uso de um composto ou de um sal farmacologicamente aceitável do mesmo, formulação inibidor do canal de sódio, métodos para tratamento e/ou prevenção de dor e de uma doença. | |
| JP2013528600A5 (hr) | ||
| RU2015107803A (ru) | Производные дигидроксипиримидинкарбоновой кислоты и их применение в лечении, облегчении или предотвращении вирусного заболевания | |
| ME01311B (me) | N-oksidi kao proljekovi 4-fenil-piridinskih derivata koji su antagonisti nki receptora | |
| HRP20161498T1 (hr) | Inhibitori kinaza i njihova upotreba u liječenju raka | |
| RU2014121090A (ru) | Модуляторы рецептора нмда и их применение | |
| RS54260B1 (en) | AMINODIHYDROTIAZINE DERIVATIVES AS BACE INHIBITORS FOR ALZHEIMER DISEASE TREATMENT | |
| AR078045A1 (es) | Derivados de pirimidina, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer | |
| ES2626555T3 (es) | Pyridone amides como moduladores de canales de sodio | |
| HRP20140214T1 (hr) | Derivati tetrahidrokinolina za lijeäśenje posttraumatskog stresnog poremeä†aja | |
| JP2013545785A5 (hr) | ||
| UY31254A1 (es) | Derivados sutituidos de n4-(5-metil-1h-pirazol-3-il)- 1,3,5-triazina-2,4-diamina, sus enantiómeros, sales farmacéuticamente aceptables de los mismos, composiciones, procesos de preparación y aplicaciones | |
| ECSP11011560A (es) | Derivados amino-propiónicos sustituidos como inhibidores de neprilisina | |
| HRP20220886T1 (hr) | Pripravci i postupci za proizvodnju pirimidina i spojeva piridina s btk inhibicijskom aktivnošću | |
| CO6470846A2 (es) | Derivados aminobut´ricos sustituidos como inhibidores de neprilisina | |
| ME01089B (me) | Derivat benzimidazola i njegova upotreba kao antagonista receptora aii | |
| UY29312A1 (es) | Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
| HRP20231369T1 (hr) | Inhibitori lsd1 i njihova medicinska upotreba | |
| HRP20191482T1 (hr) | 18f-označeni psma ciljani pet reagensi | |
| AR081426A1 (es) | Derivados de pirazol inhibidores del receptor sigma | |
| UY31885A (es) | Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones. |